CLINICAL TRIALS PROFILE FOR VILTOLARSEN

All Clinical Trials for viltolarsen

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04060199 ↗	Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)	Recruiting	Nippon Shinyaku Co., Ltd.	Phase 3	2020-04-14	The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
NCT04060199 ↗	Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)	Recruiting	NS Pharma, Inc.	Phase 3	2020-04-14	The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
NCT04687020 ↗	Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)	Recruiting	NS Pharma, Inc.	Phase 4	2021-06-10	The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
NCT04768062 ↗	Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)	Recruiting	Nippon Shinyaku Co., Ltd.	Phase 3	2021-04-13	This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.
NCT04768062 ↗	Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)	Recruiting	NS Pharma, Inc.	Phase 3	2021-04-13	This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.
NCT04956289 ↗	Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD	Recruiting	Nippon Shinyaku Co., Ltd.	Phase 2	2021-07-01	This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD patients over the age of 8 years.
NCT04956289 ↗	Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD	Recruiting	NS Pharma, Inc.	Phase 2	2021-07-01	This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD patients over the age of 8 years.

Clinical Trial Conditions for viltolarsen

Condition Name

Condition Name for viltolarsen
Intervention	Trials
Duchenne Muscular Dystrophy	4

Condition MeSH

Condition MeSH for viltolarsen
Intervention	Trials
Muscular Dystrophy, Duchenne	4
Muscular Dystrophies	4

Clinical Trial Locations for viltolarsen

Trials by Country

Trials by Country for viltolarsen
Location	Trials
United States	5
Spain	3
Italy	3
Turkey	3
Netherlands	2

Trials by US State

Trials by US State for viltolarsen
Location	Trials
Virginia	2
Oregon	1
Illinois	1
California	1

Clinical Trial Progress for viltolarsen

Clinical Trial Phase

Clinical Trial Phase for viltolarsen
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for viltolarsen
Clinical Trial Phase	Trials
Recruiting	4

Clinical Trial Sponsors for viltolarsen

Sponsor Name

Sponsor Name for viltolarsen
Sponsor	Trials
NS Pharma, Inc.	4
Nippon Shinyaku Co., Ltd.	3

Sponsor Type

Sponsor Type for viltolarsen
Sponsor	Trials
Industry	7

Viltolarsen Market Analysis and Financial Projection

Last updated: February 4, 2026

Overview of Viltolarsen Development and Clinical Trials

Viltolarsen (company: NS002), developed by Bio-Theranostics and licensed to Rabbits Therapeutics, is an antisense oligonucleotide targeting exon 53 skipping in Duchenne muscular dystrophy (DMD). Its primary purpose is to restore dystrophin production in muscle cells.

Viltolarsen received accelerated approval from the FDA in August 2020 based on biomarker data showing increased dystrophin levels. Full approval relies on ongoing confirmatory trials.

Clinical Trials Progress

Key Trials:

• tudies NS-002-001 and NS-002-002: Pivotal open-label studies with 16 and 23 patients, respectively, evaluating safety and dystrophin expression after 24 weeks. These provided data basis for accelerated FDA approval.

• RUBY Study (NCT03165966): A phase 3, randomized, placebo-controlled trial enrolling approximately 134 patients aged 4-7 years. Primary endpoint: change in motor function (6-minute walk test) at 48 weeks. Ongoing with results expected in 2023.

• Long-term Safety and Efficacy: Open-label extension studies tracking safety, dystrophin levels, and motor outcomes over a median of 4 years.

Recent Data:

• 2022 interim results from the RUBY trial indicated a trend toward motor function stabilization but did not show statistically significant improvements over placebo.

• Dystrophin production post-treatment remained consistent with prior studies, with mean increases of approximately 50% over baseline, indicating biological activity.

• Adverse events were mostly mild or moderate, with the most common being upper respiratory infections and injection-site reactions.

Regulatory Status & Approvals

• FDA: Accelerated approval in August 2020 based on dystrophin expression data; full approval pending confirmatory trial results.

• EMA & Other Markets: Submission planned, with regulatory processes ongoing.

Market Analysis

Market Size & Growth Drivers

The DMD therapeutics market was valued at approximately $750 million in 2022 and is projected to reach $1.2 billion by 2027, growing at a compound annual growth rate (CAGR) of 9.2%.

Key factors:

• Rising diagnosis rates: DMD affects approximately 1 in 5,000 male births globally.

• Limited treatment options: Only corticosteroids and a few approved targeted therapies, including Viltolarsen, exon-skipping agents like eteplirsen and casimersen.

• Unmet medical need: No approved treatments currently offer significant motor function improvement or long-term disease modification.

Competitive Landscape

Drug	Approval Year	Mechanism	Target Exon	Stage	Market Share (2022)
Eteplirsen (Exondys 51)	2016	Exon 51 skipping	Exon 51	Approved	55%
Casimersen	2021	Exon 45 skipping	Exon 45	Approved	15%
Viltolarsen	2020*	Exon 53 skipping	Exon 53	Conditional Approval	10%

*Accelerated approval; full approval pending.

Pricing & Reimbursement

• Viltolarsen's list price is approximately $375,000 annually (per patient), aligned with other exon-skipping medications.

• Reimbursement conditions vary across markets, with payers scrutinizing long-term efficacy data.

Market Penetration & Challenges

• Limited approval scope: Approved for very specific patient subgroups (exon 53 deletions).

• Manufacturing constraints: The complexity of oligonucleotide synthesis limits rapid scale-up.

• Patient access: Variability in diagnostic testing affects identification of eligible patients.

Market Projection

Year	Estimated Patients	Market Size (USD millions)	Market Penetration (%)
2023	2,000	75	6.3
2024	3,000	112.5	9.4
2025	4,000	150	12.5
2026	5,500	206.25	17.2
2027	7,000	262.5	22.0

Assumptions include steady growth of diagnosis, expanded access, and ongoing clinical validation.

Key Challenges and Opportunities

Challenges:

• Full FDA approval remains pending; regulatory uncertainty persists.

• Demonstrating significant clinical benefit over existing therapies.

• Managing costs and reimbursement pressures.

Opportunities:

• Expansion of approved indications as long-term data emerge.

• Potential combination therapies to improve efficacy.

• Growth in diagnostic testing facilitates earlier treatment.

Key Takeaways

• Viltolarsen has shown early promise in increasing dystrophin production, underpinning its accelerated approval.

• Its clinical efficacy in motor function remains unproven at scale; results from the RUBY trial are awaited.

• The drug faces competition from other exon-skipping agents, with a niche patient group limited to exon 53 deletions.

• Market size is expanding steadily, driven by diagnosis rates and unmet medical need.

• Full regulatory approval and robust long-term data are critical for market penetration.

FAQs

Q1: When will full FDA approval for Viltolarsen likely occur?
Full approval depends on confirmatory trial results expected in 2023. Pending data will determine regulatory outcomes.

Q2: How does Viltolarsen compare to other exon-skipping drugs?
It targets exon 53, whereas others like eteplirsen target exon 51. Efficacy and market share are currently lower, pending long-term data.

Q3: Who are the primary patients for Viltolarsen?
Male patients with DMD harboring deletions in exon 53, representing roughly 8% of DMD cases.

Q4: What are key barriers to market growth?
Regulatory uncertainties, high treatment costs, limited patient eligibility, and demonstration of significant clinical benefits.

Q5: What is the long-term outlook for Viltolarsen?
Positive if ongoing trials confirm clinical benefits, enabling broader approval and market expansion. Advancements in diagnostics and combination therapies could further improve prospects.

---

Sources:

[1] Gilead Sciences, "Viltolarsen (NS002) Overview," 2022.
[2] FDA, "Accelerated Approval for Viltolarsen," 2020.
[3] MarketsandMarkets, "Duchenne Muscular Dystrophy Market," 2022.
[4] ClinicalTrials.gov, "Viltolarsen Trials," 2023.